Public Health

Melissa Dunne breaks down some hard-won insights half a decade after the COVID-19 pandemic sent the world into hard lockdown.

ASAP FOR CHILDREN has published the results of its third European Rare Disease Observatory conducted by Ipsos.

The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.

Across 31 countries 44% rate the quality of the healthcare they receive as good, but access to treatment and not enough staff are seen as major systemic challenges

Unravelling the Complexities of Rare Diseases: A Market Research Perspective

The second edition of the Ipsos Generations Report finds that most people don’t know what generation they belong to, explores the business opportunities brands risk missing out on by ignoring mature adults, and demonstrates why demographic changes are no longer just a political issue

Experts in small patient populations with high unmet needs

Four years after the WHO first declared a global health emergency we look at how views on everything from inflation to mental health have changed since 2020.

There is a growing belief among the public that private corporations should also take responsibility for environmental, social, and governance (ESG) issues; these factors are no longer solely the responsibility of the public and governments. While certain business sectors are perceived as having a heightened obligation to diminish their environmental footprint (particularly energy companies, automobile manufacturers, airlines, and public transport providers), no industry can evade the necessity to act responsibly.